Replies to post #171546 on Biotech Values

[oc631]

Almost certainly the former. I don’t yet have a modeled figure for the magnitude of the Sovaldi+Ledipasvir pricing premium relative to Sovaldi+ribavirin (which is tantamount to Sovaldi alone because ribavirin is available everywhere as a cheap generic).

My comments may be premature since we haven't seen the breakdown between GT1A and GT1B patients or future Sofo/Ledi labeling. You suggest GILD will be adverse to the idea of 8-week dosing for commercial reasons yet this idea may be one-sided. Pricing 12-weeks of Sofo/Ledi above $84,000 (12w/Sofo/Riba pricing in GT2/GT3) may be untenable and leave ABBV too much room to price competitively. Perhaps 8-weeks of Sofo/Ledi at pricing parity across genotypes is in the cards and this would justify premium pricing for 12-weeks. A price markedly higher than $84K for 12-weeks of Sofo/Ledi, without offering a 8-week option, may serve our best interests as ENTA shareholders but I'm doubtful this will happen.